Perspective Therapeutics (NYSE:CATX) Upgraded to "Strong-Buy" at Lifesci Capital

Lifesci Capital upgraded shares of Perspective Therapeutics (NYSE:CATX - Free Report) to a strong-buy rating in a research note released on Saturday morning,Zacks.com reports.

CATX has been the topic of a number of other reports. HC Wainwright reissued a "buy" rating and set a $10.00 price objective on shares of Perspective Therapeutics in a report on Monday, March 31st. Truist Financial decreased their price objective on Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Royal Bank Of Canada raised Perspective Therapeutics from an "outperform" rating to a "moderate buy" rating and raised their price objective for the company from $15.00 to $16.00 in a report on Tuesday, June 3rd. Wedbush reissued an "outperform" rating and set a $11.00 price objective on shares of Perspective Therapeutics in a report on Monday, June 23rd. Finally, B. Riley restated a "buy" rating and set a $12.00 price target (up from $9.00) on shares of Perspective Therapeutics in a research report on Monday, June 23rd. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, Perspective Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $12.56.

Perspective Therapeutics Stock Performance

Shares of NYSE:CATX traded up $0.18 on Friday, hitting $4.08. The company's stock had a trading volume of 763,558 shares, compared to its average volume of 1,088,909. The company has a 50-day simple moving average of $3.18 and a 200 day simple moving average of $2.89. Perspective Therapeutics has a 1 year low of $1.60 and a 1 year high of $16.55.

Institutional Trading of Perspective Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of CATX. National Bank of Canada FI increased its stake in shares of Perspective Therapeutics by 549,900.0% during the fourth quarter. National Bank of Canada FI now owns 11,000 shares of the company's stock valued at $35,000 after buying an additional 10,998 shares during the period. ProShare Advisors LLC increased its stake in shares of Perspective Therapeutics by 49.1% during the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company's stock valued at $49,000 after buying an additional 5,011 shares during the period. Mercer Global Advisors Inc. ADV purchased a new position in shares of Perspective Therapeutics during the fourth quarter valued at approximately $51,000. Corton Capital Inc. purchased a new position in shares of Perspective Therapeutics during the fourth quarter valued at approximately $61,000. Finally, Wexford Capital LP purchased a new position in shares of Perspective Therapeutics during the fourth quarter valued at approximately $64,000. Institutional investors own 54.66% of the company's stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.